Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function?
Authors:
- Carla Leal MoreiraCMCarla Leal Moreira
- Liliana CunhaLCLiliana Cunha
- Sofia CorreiaSCSofia Correia
- Filipa SilvaFSFilipa Silva
- Ana CastroACAna Castro
- Joana TavaresJTJoana Tavares
- Maria João CarvalhoMCMaria João Carvalho
- José Carlos OliveiraJOJosé Carlos Oliveira
- Olívia SantosOSOlívia Santos
- António CabritaACAntónio Cabrita
- Anabela RodriguesARAnabela Rodrigues
Open Access
- 1 March 2020
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 42 (1) , 31-37
Abstract
Introduction: It has been suggested that cystatin C levels are modified by obesity and inflammation. Furthermore, cystatin C has been associated with cardiovascular events and mortality outcomes. Aim: To study the association of cystatin C with the metabolic profile and cardiovascular disease of peritoneal dialysis patients. Methods: Data collected included clinical, laboratorial, and multifrequency bioimpedance assessment of 52 stable peritoneal dialysis patients. Minimal residual renal function was defined as > 2mL/min/1.73m2. Results: Serum cystatin C was not significantly associated with peritoneal or urinary cystatin C excretion. Negative correlation of cystatin C with normalized protein catabolic rate (rho -0.33, p = 0.02) and a trend towards positive correlation with relative body fat (rho 0.27, p = 0.05) were not independent from residual renal function. Cystatin C was not significantly associated with cardiovascular disease (p = 0.28), nor with glycated hemoglobin (p = 0.19) or c-reactive protein (p = 0.56). In the multivariate model, both age and diabetes were the strongest predictors of cardiovascular disease (odds ratio 1.09, p = 0.029 and odds ratio 29.95, p = 0.016, respectively), while relative body fat was negatively associated with cardiovascular disease (p = 0.038); neither cystatin C (p = 0.096) nor minimal residual renal function (p = 0.756) reached a significant association with cardiovascular disease. Conclusions: In this group of peritoneal dialysis patients, cystatin C did not correlate with the metabolic or inflammatory status, nor cardiovascular disease, after adjustment for residual renal function.Keywords
This publication has 25 references indexed in Scilit:
- Clinical Utility of Creatinine- and Cystatin C–Based Definition of Renal Function for Risk Prediction of Primary Cardiovascular Events in Patients With DiabetesDiabetes Care, 2012
- Filtration Markers May Have Prognostic Value Independent of Glomerular Filtration RateJournal of the American Society of Nephrology, 2012
- Estimated GFR Associates with Cardiovascular Risk Factors Independently of Measured GFRJournal of the American Society of Nephrology, 2011
- Cathepsins and cystatin C in atherosclerosis and obesityBiochimie, 2010
- Cystatin C and Long-Term Mortality Among Subjects With Normal Creatinine-Based Estimated Glomerular Filtration RatesJACC, 2010
- Association of Dialysis Modality and Cardiovascular Mortality in Incident Dialysis PatientsClinical Journal of the American Society of Nephrology, 2009
- Reversible Fanconi syndrome due to lenalidomide.Clinical Kidney Journal, 2008
- Body fluid volume determination via body composition spectroscopy in health and diseasePhysiological Measurement, 2006
- A new technique for establishing dry weight in hemodialysis patients via whole body bioimpedanceKidney International, 2002
- Cross-sectional Assessment of Weekly Urea and Creatinine Clearances in Patients on Continuous Ambulatory Peritoneal DialysisASAIO Journal, 1992